Welcome to Progress in Neurology and Psychiatry’s dedicated website. Progress is for health professionals in secondary and primary care looking after patients with neurological and psychiatric diseases. If you are a health professional working in the field of neurology or psychiatry you can register with us for free access to our content.Sign up for e-alerts and print copies

Latest News

US approves galcanezumab for cluster headache

The Food and Drug Agency in the USA, has approved galcanezumab-gnlm, Lilly’s monoclonal antibody targeting calcitonin gene-related peptide, for the treatment...Read more

Brexit impacts mental health in Scotland

Brexit is taxing not only the patience but also the mental health of Europeans living in Scotland, research from Aberdeen’s Robert Gordon University has...Read more

Utilisation of antipsychotics

An analysis of medical database records in the UK, Italy, Spain and the United States involving a total of 1.4 million patients with schizophrenic disorder and...Read more

Online intervention for depression in people with epilepsy

Anxiety and depression are highly prevalent among people with epilepsy. Many do not have access to a professional who can offer cognitive therapy, say...Read more

Depression and overweight/obesity

Two studies in people who are overweight or obese have sought to determine the impact of psychological and/or pharmacological interventions on symptoms of...Read more

Long term benefit in myasthenia gravis

Treatment of anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis with the anti-complement monoclonal antibody eculizumab is...Read more

Guidance on rescheduling gabapentin and pregabalin

NHS England has published guidance on managing the rescheduling of gabapentin and pregabalin as Schedule 3 Controlled Drugs...Read more

Featured Articles

The use of biomarkers in Alzheimer’s disease: a case report
Uncertainties remain around the use of biomarkers in clinical practice to diagnose Alzheimer’s disease. There are several implications for both patients and clinicians, including the ethical and practical dilemmas of identifying a disease process early in its course when there are no disease-modifying treatments available.
Click here to view

Buprenorphine patches: impact on cognitive functions in Down’s syndrome
Opioids have been regarded as among the most effective medications for the treatment of acute, chronic severe pain and cancer pain. However, the long-term administration of opioids continues to be controversial. Dr Javaid et al report of a case of a woman with Down’s syndrome and severe learning disability presenting with symptoms of dementia, due to the possible likelihood of prolonged use of buprenorphine patches, over the five years.
Click here to view

Anti-CGRP monoclonal antibodies: breakthrough in migraine therapeutics
Migraine is considered as one of the most debilitating neurological disorders but the success of the anti-calcitonin gene-related peptide (CGRP) therapies marks a new era in the treatment of migraine and has paved way for further research into the exact pathophysiology of migraine. Here, the authors discuss their literature review on the anti-CGRP therapies to examine the pathophysiology of migraine, with a focus on the possible role of CGRP and the safety and efficacy of monoclonal antibodies targeting it
Click here to view

Web design and marketing agency Leamington Spa